|
IGMS | Igm Biosciences, Inc. |
|
|
IGMS | Igm Biosciences, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.31 |
| Leverage | 5.66% |
| Market Cap | $ 77.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -53.0m |
| Margin | -1652.64% |
IGM Biosciences, Inc., a biotechnology company, develops immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. The company is headquartered in Mountain View, California.